OGN:NYSE, Organon & Co.
OGN stock overview
Organon & Co. (OGN:NYSE) closed at $13.89 on November 20, 2026,
down 0.14% on the day.
The stock trades 0.4% below its 52-week high of $13.94
and 144.1% above its 52-week low of $5.69.
Over the past year, it gained 96.7%.
Organon & Co. is part of the Health Care sector.
Key figures
- Price
- $13.89
- Day change
- -0.14%
- Volume
- 3,572,950
- Average volume
- 2,712,434
- Market cap
- 3B+
- 52-week range
- $5.69 – $13.94
- 50-day average
- $13.77
- 200-day average
- $11.87
Price action over the past year
In 252 trading sessions since November 20, 2025, OGN closed higher on 123 days (49%).
Its best day was April 24, 2026 (+30.93%) and its worst was February 12, 2026 (-8.19%).
The stock moved 10% or more in a single session 4 times.
It opened at least 5% above the previous day's high 3 times.
Recent signals
OGN news
-
Nov 12, 2026:
Organon Presents New Analysis of Pooled Post-Hoc Phase 3 Data on VTAMA® (tapinarof) cream, 1%, Demonstrating Consistent Efficacy in Atopic Dermatitis Across Diverse Patient Subgroups at ACAAI
-
Nov 12, 2026:
Organon Presents New Analysis of Pooled Post-Hoc Phase 3 Data on VTAMA (tapinarof) cream, 1%, Demonstrating Consistent Efficacy in Atopic Dermatitis Across Diverse Patient Subgroups at ACAAI
-
Nov 10, 2026:
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
-
Nov 7, 2026:
New Real-World Evidence Presented by Organon at the American College of Rheumatology (ACR) Annual Meeting Evaluated a Large-Scale Switch to HADLIMA® (adalimumab-bwwd) Across United States Veterans Affairs Healthcare System
-
Nov 7, 2026:
New Real-World Evidence Presented by Organon at the American College of Rheumatology (ACR) Annual Meeting Evaluated a Large-Scale Switch to HADLIMA (adalimumab-bwwd) Across United States Veterans Affairs Healthcare System
-
Nov 5, 2026:
Organon to Present New Analysis on VTAMA® (tapinarof) cream, 1% at the 2026 American College of Allergy, Asthma & Immunology Annual Scientific Meeting
-
Nov 5, 2026:
Organon to Present New Analysis on VTAMA (tapinarof) cream, 1% at the 2026 American College of Allergy, Asthma & Immunology Annual Scientific Meeting
-
Nov 2, 2026:
Betting On Drug Sales: Is Viatris Or Lilly The Better Way In?
About Organon & Co.
Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. Its two operating segments are the Organon Products segment and the Merck Retained Products segment. It operates in the United States, China, Japan, Korea, and countries in Europe.
Similar stocks
Find more stocks like OGN with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.